Frédéric Joliot Institute for Life Sciences - On the same theme

L’imagerie TEP révèle les effets de la kétamine sur la plasticité synaptique dans un modèle de dépression

Mon, 22 Dec 2025 11:00:00 GMT

Des chercheurs de BioMaps (SHFJ) et de MOODS ont validé une approche innovante de neuroimagerie moléculaire permettant de suivre, de manière non-invasive, les effets de la kétamine sur la densité synaptique dans un modèle préclinique de dépression.

Reconstructing PET images more reliably with a convergent “Plug-and-Play” regularization approach

Tue, 16 Dec 2025 11:00:00 GMT

A team of researchers from BioMaps (SHFJ) is proposing a new reconstruction method for PET imaging that combines optimization algorithms with deep neural networks. Their “plug-and-play” regularization approach ensures improved image quality thanks to PET-specific reconstruction learning, while guaranteeing stability and robustness—two critical aspects in the use of AI-based medical techniques.

PET imaging of OATP transporter-mediated drug elimination: impacts of sex and age

Wed, 15 Oct 2025 10:00:00 GMT

Researchers from BioMaps (SHFJ) investigated the hepatic activity of organic anion-transporting polypeptides (OATPs), key players in the elimination of certain drugs, using a PET imaging approach with 11C-glyburide, which revealed differences in tracer pharmacokinetics between men and women.

Développement de radioligands pour l’imagerie TEP de la neuroinflammation

Fri, 03 Oct 2025 10:00:00 GMT

Des chercheurs du SHFJ, en collaboration avec le CEA-Jacob, le CRN à Lyon et le PharmaCenter à Bonn ont imaginé, synthétisé et caractérisé deux radiotraceurs TEP ciblant P2Y12, une protéine impliquée dans l’activation de la microglie durant la neuroinflammation.

Better understanding opioid tolerance through brain imaging

Wed, 06 Aug 2025 10:00:00 GMT

A study combining PET imaging and pharmacology, conducted by researchers at BioMaps (SHFJ), suggests that decreased availability of opioid receptors and altered neuronal energy metabolism constitute molecular signatures of opioid tolerance. These observations, made in an animal model, could help improve understanding and treatment of opioid dependence.

Correlation between neuroinflammation and epileptogenic zone in drug-resistant focal epilepsy

Tue, 15 Jul 2025 10:00:00 GMT

A study by SHFJ researchers has established a strong correlation between biomarkers of neuroinflammation, revealed by original PET imaging, and intracranial electroencephalographic recordings of epileptogenic activity. This offers hope for drug-resistant patients who are candidates for surgery.

Une méthode d’analyse en IRM de diffusion pour étudier les altérations des faisceaux de substance blanche dans la maladie d’Alzheimer et la pathologie LATE ?

Wed, 11 Jun 2025 10:00:00 GMT

Des chercheurs du SHFJ, de NeuroSpin et du GHU Paris Psychiatrie & Neurosciences mettent en évidence des différences dans les altérations des faisceaux de substance blanche entre des patients diagnostiqués Alzheimer et d’autres vraisemblablement atteints de la pathologie LATE.

Theranostic antibodies targeting endothelin receptors in preclinical models of glioblastoma and melanoma

Thu, 22 May 2025 10:00:00 GMT

Researchers from SPI (DMTS) propose immunodiagnostic and immunotherapeutic approaches based on the use of innovative antibodies targeting two subtypes of endothelin receptors (ETA and ETB), recognised as relevant therapeutic targets in oncology.

Study of subcortical neuromodulatory systems alteration in Alzheimer's disease and related disorders

Wed, 16 Oct 2024 10:00:00 GMT

A team from GHU Paris and SHFJ has used brain MRI to study the integrity of the locus coeruleus and nucleus basalis of Meynert in patients with early-onset Alzheimer's disease (AD), age-related TDP-43 encephalopathy (LATE) and fronto-temporal dementia (FTD). Both structures are altered in early AD, LATE and probably FTD, making these neuromodulatory areas potential therapeutic targets

PET image reconstruction by deep learning with uncertainty estimation in the ClearMind gamma photon detector

Mon, 07 Oct 2024 10:00:00 GMT

Three DES and DRF laboratories have developed an innovative Machine Learning algorithm to improve the reconstruction of PET images acquired as part of the ClearMind project, a technology based on the detection of gamma photons by a monolithic lead tungstate crystal detector. A step towards more accurate PET imaging

PET imaging evaluation of the central effects of a drug-candidate to aid smoking cessation

Thu, 29 Aug 2024 10:00:00 GMT

A BioMaps team has used PET imaging to monitor glucose metabolism as a marker of the cerebral impact of smoking cessation, as well as the effects of a promising drug-candidate for the treatment of such cessation. By revealing the restoration of normal activity in the brain area associated with craving, these results offer hope for smoking cessation in humans

Response to intra-tumoral immunotherapy assessed by immunoPET in mice

Fri, 19 Apr 2024 10:00:00 GMT

A team from BioMaps (SHFJ), in partnership with the Gustave Roussy Institute, has used immunoPET imaging to assess the influence of tissue distribution on the efficacy of cancer immunotherapy, administered intra-tumor and intravenously in mice. Intratumoral administration is more effective and reduces overall exposure of organs at risk

Impact of metabolic variations on PET imaging of neuroinflammation in humans

Thu, 12 Oct 2023 10:00:00 GMT

Researchers at BioMaps evaluated the effect of several factors on the distribution of [18F]DPA-714 in 201 subjects who participated in SHFJ PET imaging protocols to better understand the role of neuroinflammation in various neurological diseases. They conclude that measures of individual metabolism are important in image interpretation.

PET imaging monitoring of an antibody targeting endothelin receptors expressed by glioblastoma tumors

Thu, 07 Sep 2023 10:00:00 GMT

Researchers at BioMaps (SHFJ) and SPI (DMTS) have studied the pharmacokinetics of a novel immuno-radioligand targeting the endothelin A receptor (ETA), overexpressed in many cancers, particularly glioblastoma. The immunoPET imaging approach used in this study in a preclinical model confirms the theranostic potential of this antibody.

Longitudinal monitoring of tauopathy in PET imaging to better understand the various modalities of clinical evolution of Alzheimer's disease

Wed, 02 Aug 2023 10:00:00 GMT

A joint team from GHU Paris and BioMaps (SHFJ) conducted a 2-year longitudinal study of 27 people with Alzheimer's disease, tracking the progression of tau pathology measured by PET imaging, of cortical atrophy using MRI, and their links with cognitive decline.

The "rabbit motif" in 18F-DOPA PET imaging for a simplified diagnostic evaluation of parkinsonian syndromes

Tue, 23 May 2023 10:00:00 GMT

BioMaps researchers compared the diagnostic performance of the rabbit visual pattern observed in 18F-DOPA PET imaging with the standard procedure approved by the international nuclear imaging societies for the diagnosis of parkinsonian syndromes in PET/MRI and obtained encouraging results, which may validate the clinical utility of such a model

Radiomarquage du crizotinib au fluor-18 : un nouvel outil pour suivre par TEP la biodistribution de ce médicament

Thu, 27 Apr 2023 10:00:00 GMT

Des chercheurs du SHFJ ont mis au point la radiosynthèse au fluor-18 du crizotinib, un médicament qui ne pénètre pas dans le cerveau. Ce nouvel outil pour l’imagerie TEP permettra d’explorer de futures stratégies visant à faire passer la barrière hémato-encéphalique à ce médicament pour traiter certaines métastases cérébrales.

Platinum nanoparticles to improve radiotherapy ? PET imaging provides answers

Tue, 21 Feb 2023 11:00:00 GMT

Researchers from the SHFJ laboratory at ISMO have demonstrated the value of platinum nanoparticles as potential radiosensitizing agents for radiation therapy.

Development of a new radiolabeling strategy in immunoPET for precision imaging

Tue, 21 Feb 2023 11:00:00 GMT

Researchers from the BioMaps laboratory (SHFJ) and the Molecular Engineering for Health Service (SIMoS, DMTS) developed an enzymatic approach for radiofluorination of an anti-PD-L1 Fab and compared its in vivo properties to the same Fab stochastically labeled by two conventional methods.

Glioblastoma: Does focused ultrasound increase the therapeutic efficacy of cetuximab?

Wed, 15 Feb 2023 11:00:00 GMT

Researchers from the SHFJ, in collaboration with NeuroSpin, show that the use of focused ultrasound does not increase the therapeutic effects of cetuximab on glioblastoma although the opening of the blood-brain barrier is transiently effective.

A novel fluorine-18 thiol carrier for labeling biomolecules used in PET imaging

Tue, 28 Jun 2022 10:00:00 GMT

Radiochemists from the BioMaps unit (SHFJ) have developed and automated the synthesis of an 18F-fluoropyridine containing a thiol function (-SH), allowing its conjugation to model biomolecules within 45 minutes. A step towards rapid radiolabeling of complex biological molecules for PET imaging.

New radioligands for anti-PD-1/PD-L1 immunoPET

Tue, 12 Apr 2022 10:00:00 GMT

Researchers from the SHFJ and the DMTS have developed optimized radioligands for immunoPET imaging. The objective is to better predict the effectiveness of anti-PD1/anti-PDL1 immunotherapy used to fight certain cancers.

Hybrid PET/MRI imaging, a unique examination to improve the detection of epileptogenic lesions

Tue, 05 Apr 2022 10:00:00 GMT

A team from BioMaps (SHFJ), in collaboration with several hospital groups, shows that hybrid PET/MRI imaging significantly improves the detection of epileptogenic foci and, consequently, the outcome of surgical treatment of epilepsy.

Alzheimer's: PET imaging of tau protein predicts cognitive decline and progression of brain atrophy

Sun, 03 Apr 2022 10:00:00 GMT

A joint team from GHU Paris and SHFJ shows the predictive value of PET imaging data of the Tau protein in the progression of Alzheimer's disease.

7T Sodium MRI confirms early metabolic damage in Alzheimer's disease

Mon, 07 Mar 2022 11:00:00 GMT

7T Sodium MRI may well prove increasingly useful in the study of physiological processes in inflammatory and neurodegenerative diseases and brain tumors. An example is a study on Alzheimer's disease, led by a NeuroSpin team.

Multiparametric PET-MRI imaging: toward a biological characterization of tumors at the supervoxel level

Wed, 10 Nov 2021 11:00:00 GMT

A collaborative study led by BioMaps researchers (SHFJ) demonstrates that fully integrated quantitative multiparametric analysis of non-small cell lung cancer in hybrid 18F-FDG PET/MRI 3T imaging is clinically feasible and could enable biological characterization of tumors at the supervoxel scale.

PET imaging of tau and amyloid deposits improves the diagnosis of progressive amnesia

Thu, 04 Nov 2021 11:00:00 GMT

Researchers from BioMaps (SHFJ) and the Service de Neurologie de la Mémoire et du Langage (Hôpital Ste-Anne) show, through amyloid and tau molecular imaging in patients followed for 2 years, that the diagnosis of progressive amnesia in the elderly is not necessarily Alzheimer's disease and may be caused by other mechanisms clearly distinguishable from it.

Characteristics of the initial symptoms of Alzheimer's disease in young patients

Thu, 10 Jun 2021 10:00:00 GMT

Researchers from BioMaps (SHFJ) and the Department of Memory and Language Neurology (Ste Anne's Hospital) studied the early clinical signs of Alzheimer's disease (AD) reported by young patients (< 62 years old) compared to those reported in classic AD of the elderly (> 65 years old). They show that these signs are misleading and often appear in the professional context.

PET imaging reveals the neuropharmacology of buprenorphine

Wed, 05 May 2021 10:00:00 GMT

Researchers at BioMaps (SHFJ) have succeeded in determining the interaction dynamics of buprenorphine, an opioid drug with a particularly complex pharmacology, with its brain receptors in vivo. To do so, they developed an original PET imaging approach based on the use of the radiolabeled molecule (11C-buprenorphine).

Permeabilizing the blood-brain barrier to deliver therapeutic antibodies into the brain? ImmunoPET imaging provides answers

Tue, 06 Oct 2020 10:00:00 GMT

Researchers from SHFJ, NeuroSpin and DMTS have demonstrated, by immunoPET imaging, the impact of transient BBB permeabilization on brain exposure to an anti-EGFR antibody. Promising prospects for targeted immunotherapy of glioblastoma.

Mapping of normal brain aging: unprecedented results from the SENIOR cohort

Tue, 04 Aug 2020 10:00:00 GMT

The SENIOR study, conducted by several NeuroSpin teams, consists in monitoring, since March 2012, a cohort of 100 subjects aged 50 to 70 years by annual MRI imaging over a period of 10 years, to establish a normal aging brain imaging biomarkers mapping. This publication in Alzheimer's Research & Therapy describes the baseline experimental protocol and presents first promising results.

Innovative approach to radiolabel peptides with fluorine-18 for PET imaging

Mon, 17 Feb 2020 11:00:00 GMT

Radiochemists from the BioMaps unit (SHFJ) have developed and automated a new fluor-18 radiolabelling method for peptides used to characterize specific pathological molecular signatures and thus target treatments. Peptides were conjugated to a specific tag, then radiolabeled in a single step under mild conditions, making this approach an innovative solution for PET imaging of peptides labeled with fluorine-18.

Alzheimer's: a more effective method to diagnose the disease?

Fri, 20 Sep 2019 10:00:00 GMT

A study conducted by Maxime Bertoux (Unit 1171 Inserm / Lille University / CHU Lille) in collaboration with researchers from the Centre Hospitalier Saint Anne, the SHFJ (CEA-Joliot), NeuroSpin (CEA-Joliot) and the ICM shows that the morphological analysis of the cortical sulci would make it possible to recognize Alzheimer's disease in 91% of the cases, against 80% now by anatomical analysis of the cortex.

See a tumor in PET imaging by « click-chemistry » in vivo

Tue, 03 Sep 2019 10:00:00 GMT

A new PET imaging method by antibody pretargeting was developed at SHFJ, in collaboration with teams of SCBM and SPI. It consists in reacting in vivo a molecule labeled with 18Fluor with an antibody previously fixed on a tumor and this, in an extremely fast and selective manner, thanks to a « click-chemistry » reaction. The very good results obtained allow to consider the use of pre-targeted antibodies in nuclear medicine.

A new biomarker to predict tumor progression from whole body PET images.

Tue, 16 Jul 2019 10:00:00 GMT

The SHFJ/IMIV laboratory (Inserm 1023/CNRS/CEA/UP-Sud), in collaboration with hospital-university teams, has shown that, in patients with advanced-stage large cell lymphoma (B type), automatic quantitative measurements of tumor dissemination detected by whole-body PET imaging have a predictive value of progression-free survival (tumor stabilization) and overall survival.

Towards a better detection of glioblastoma infiltration

Tue, 26 Feb 2019 11:00:00 GMT

Glioblastoma is a very aggressive cancer of the central nervous system, mainly because of its ability to infiltrate the surrounding areas. A collaboration led by a team of SHFJ and involving NeuroSpin demonstrates the interest of two imaging techniques for the early detection of tumor infiltration.

"Mini-brains" for research on Alzheimer's disease

Mon, 14 Jan 2019 11:00:00 GMT

A partnership between the François Jacob Institute of Biology/CEA, The Frédéric Joliot Institute for Life Sciences/CEA and CellTechs (a Sup'Biotech lab) has led to a new approach for modeling Alzheimer's disease in vitro.

Evolution of Alzheimer's disease : a dual role of the neuroimmune reaction

Thu, 10 Jan 2019 11:00:00 GMT

A collaboration involving the Sainte-Anne Hospital, the SHFJ, the Saint-Antoine research center and the ICM identified, through a PET brain imaging study in patients with Alzheimer's disease, two distinct kinetic profiles of the cerebral neuroimmune response, that impact the disease progression differently. Researchers propose an original model of neuroinflammation, likely to open new therapeutic avenues.

Physicists and pharmacologists join forces to better understand the biology of the blood-brain barrier.

Thu, 20 Dec 2018 11:00:00 GMT

Thanks to complementary imaging techniques, researchers from the SHFJ and NeuroSpin have shown that the physical blood-brain barrier (BBB) disruption is not necessarly enough to deliver some drugs into the brain, especially when there are recognized and supported by efflux transporters.

LIFEx increasingly popular for characterizing tumor heterogeneity in medical imaging

Thu, 05 Jul 2018 10:00:00 GMT

IMIV unit (SHFJ), in collaboration with the Gustave Roussy Institute, has developed the free software platform LIFEx that allows to characterize the tumor heterogeneity from any type of medical images: PET, MRI, scanner, ultrasound. With nearly 900 members, this platform has an international success because it facilitates the realization of radiomic studies, conducted in the context of personalized medicine.

18F-Fludarabine for Lymphoma Imaging: A First Clinical Study

Wed, 23 May 2018 10:00:00 GMT

The SHFJ LDM-PET team (GIP Cyceron, Caen), in collaboration with the University Hospital of Caen, successfully used, for the first time in the clinic, the radiopharmaceutical drug developed and produced by the researchers of the team. , the [18F] Fludarabine. This drug, which is innovative for lymphoproliferative diseases, has been shown to be more effective in terms of specificity and sensitivity than its current counterpart, [18F] FDG.

A pharmacokinetic model for more accurate PET imaging of neuroinflammation

Thu, 22 Feb 2018 11:00:00 GMT

Research Teams from SHFJ, MIRCen and NeuroSpin tested a pharmacokinetic analysis model of Positron-emission tomography (PET) data at 18F-DPA-714, taking into account endothelial cell activity not specifically associated with an inflammatory state. This model allows a more precise interpretation of PET images of neuroinflammation present in most neurodegenerative pathologies.

PET reveals brain damage related to alcohol

Tue, 07 Nov 2017 11:00:00 GMT

A Research Team from the SHFJ (IMIV) highlights, through a preclinical model of exposure to alcohol, an immediate and persistent neuro-immune response, several months after the initial exposure of alcohol. These results confirm the occurrence of brain damage that may play a key role in the neurological deficits reported in teenagers who like "binge-drinking", that is to say an excessive consumption of alcohol over a very short time.

New method for quantifying images in PET / MRI

Fri, 30 Jun 2017 10:00:00 GMT

Deriving from a collaboration between the SHFJ and MIRCen, this work presents a new and original method of quantification of positron emission tomography (PET) images adapted to hybrid PET / MRI cameras, developed by combining the expertise of MIRCen in MRI preclinical and SHFJ expertise in preclinical PET.

"It happened at the SHFJ"

Tue, 27 Jun 2017 10:00:00 GMT

The "First international course on PET in Epilepsy", organized by the SHFJ in early June, brought together about thirty international specialists in the field. The challenge was to disseminate know-how widely developed at SHFJ: the pre-surgical localization of epileptic foci by PET in patients with focal drug-resistant epilepsies, candidates for resection neurosurgery.

Measuring tumor heterogeneity from PET images: a first biological validation

Fri, 03 Jun 2016 07:00:00 GMT

Recent work from the IMIV research lab suggests that tumor heterogeneity measured in vivo using PET images actually reflects the biological heterogeneity as measured ex vivo using pathological slides.

Early and protective microglial activation in Alzheimer's Disease.

Thu, 17 Mar 2016 08:00:00 GMT

For the first time in human, a study proves that microglial activation seems to play a protective role in the clinical progression of the disease at these early stages of Alzheimer's disease.

Modulating cerebral cholesterol: a new avenue of research to treat Alzheimer’s disease?

Mon, 14 Sep 2015 10:00:00 GMT

Two French research teams have recently shown in a rodent model that overexpression of an enzyme capable of eliminating excess cholesterol in the brain can act in a beneficial way on the tau component of the disease to completely correct it.